New Zealand sets up research group to improve innovative capacity:
This article was originally published in Clinica
The Research Infrastructure Advisory Group (RIAG) has been founded in New Zealand to advise the government on science and technology funding. New Zealand needs to adapt to changing research trends such as investment needed for more sophisticated research equipment and increased dependence on international collaboration. There is need for a funding model to suit new research trends and a method to secure cost-benefit from research undertaken. The Ministry of Research, Science and Technology (MoRST) told Clinica that RIAG will "provide expert advice to MoRST on the scientific case for, and strategic relevance of, high-cost items of research infrastructure".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.